

| ANALYTE | REFERENCE RANGE (LOW RISK) | ALERT RANGES (MODERATE OR ELEVATED RISK) | RESULTS QUALIFIERS (Newborn screening results are not diagnostic. Screen positive results must be confirmed by diagnostic testing and clinical evaluation.) |
|---------------------------------|---|---|--|
| Carnitine (C0) | C0 > 6.0 µmol/L | C0 ≤ 6.0 µmol/L – Elevated | Acylcarnitine results are included in the tests Fatty Acid Profile and Organic Acid Profile. A reference range of "Profile" for these tests indicates that results are within reference range. Acylcarnitine analyte results that are outside reference range will be displayed on reports. Results of the Fatty Acid Profile and Organic Acid Profile tests will be reported as Inconclusive if age at time of specimen collection is less than 24 hours . |
| Propionylcarnitine (C3) | C3 < 5.0 µmol/L and C3/C2 < 0.3 | 5.0 ≤ C3 < 8 µmol/L and C3/C2 ≥ 0.3 – Moderate 8 ≤ C3 < 10 µmol/L and C3/C2 < 0.3 – Moderate 8 ≤ C3 < 10 µmol/L and C3/C2 ≥ 0.3 – Elevated C3 ≥ 10 µmol/L – Elevated | |
| Isovalerylcarnitine (C5) | C5 < 1.0 µmol/L | C5 ≥ 1.0 µmol/L – Elevated | |
| Glutaryl carnitine (C5DC) | C5DC < 0.8 µmol/L | C5DC ≥ 0.8 µmol/L – Elevated | |
| 3-OH Isovalerylcarnitine (C5OH) | C5OH < 0.8 µmol/L | C5OH ≥ 0.8 µmol/L – Elevated | |
| Octanoylcarnitine (C8) | C8 < 0.6 µmol/L | C8 ≥ 0.6 µmol/L – Elevated | |
| Tetradecenoylcarnitine (C14:1) | C14:1 < 0.8 µmol/L | C14:1 ≥ 0.8 µmol/L – Elevated | |
| Palmitoylcarnitine (C16) | C16 < 8.5 µmol/L | C16 ≥ 8.5 µmol/L – Elevated | |
| 3-OH-Palmitoylcarnitine (C16OH) | C16OH < 0.09 µmol/L | C16OH ≥ 0.09 µmol/L – Elevated | |
| Arginine (ARG) | ARG < 110 µmol/L | ARG ≥ 110 µmol/L – Elevated | Results for succinyl acetone, citrulline, and amino acids are included in the test, Amino Acid Profile. A reference range of "Profile" for these tests indicates that results are within reference range. Results of newborn screening for Amino Acid Profile analytes will be reported as Inconclusive if multiple (more than one) amino acid result value is outside reference range (XAA) or if age at time of specimen collection is less than 24 hours . |
| Citrulline (CIT) | CIT < 75 µmol/L | CIT ≥ 75 µmol/L – Elevated | |
| Leucine (LEU) | LEU < 400 µmol/L | LEU ≥ 400 µmol/L – Elevated | |
| Methionine (MET) | MET < 100 µmol/L | MET ≥ 100 µmol/L – Elevated | |
| Phenylalanine (PHE) | PHE < 160 µmol/L | PHE ≥ 160 µmol/L – Elevated | |
| Tyrosine (TYR) | TYR < 400 µmol/L | TYR ≥ 400 µmol/L – Elevated | |
| Succinylacetone (SuAc) | SuAc < 1.7 µmol/L | SuAc ≥ 1.7 µmol/L – Elevated | |
| 17-OH-progesterone (17-OH-P) | 17-OH-P < 120 ng/mL S and > 0.5 ng/mL S | 17-OH-P ≥ 120 ng/mL S for infant weighing 1500 g or less – Elevated | 17-OH-progesterone results will be reported as Inconclusive if weight and/or age at time of collection are not provided. 17-OH-P results are reported as ng/mL S, where S denotes serum, and are calculated (not actually measured in serum) based on conversion factors that assume 55% hematocrit (actual hematocrit is not measured). |
| | 17-OH-P < 90 ng/mL S and > 0.5 ng/mL S | 17-OH-P ≥ 90 ng/mL S for infant weighing 1501-2000 g – Elevated | |
| | 17-OH-P < 75 ng/mL S and > 0.5 ng/mL S | 17-OH-P ≥ 75 ng/mL S for infant weighing 2001-2500 g – Elevated | |
| | 17-OH-P < 35 ng/mL S and > 0.5 ng/mL S | 17-OH-P ≥ 35 ng/mL S for infant weighing 2501 g or more – Elevated | |
| | | 17-OH-P ≥ 240 ng/mL S for infant of any weight - Elevated | |
| GALC | > 0.65 µmol/L/hr | ≤ 0.65 µmol/L/hr – Elevated | The Lysosomal Storage Disorder test includes results of newborn screening for Krabbe (GALC analyte), MPS1 (IDUA analyte) and Pompe (GAA analyte). A reference range of "Profile" for this test indicates that all results are within reference range. Analyte results that are outside reference range will be displayed on reports. Results for GALC will not be displayed if newborn screening for Krabbe has been refused and this is indicated by "Not Tested" on the report. If results for more than one analyte included in the Lysosomal Storage Disorder test is outside reference range, results for IDUA and GAA will be reported as Inconclusive and results for GALC will be reported as Elevated Risk. |
| IDUA | > 0.65 µmol/L/hr | ≤ 0.65 µmol/L/hr – Elevated | |
| GAA | > 1.10 µmol/L/hr | ≤ 1.10 µmol/L/hr – Elevated | |

effective 10/23/2022

| ANALYTE | REFERENCE RANGE (LOW RISK) | ALERT RANGES (MODERATE OR ELEVATED RISK) | RESULTS QUALIFIERS (Newborn screening results are not diagnostic. Screen positive results must be confirmed by diagnostic testing and clinical evaluation.) |
|-----------------------|---|--|--|
| TSH | For specimens collected at ≥ 24 and ≤ 48 hours of age: $\mu\text{U/mL S} \leq \text{TSH} < 34 \mu\text{U/mL S}$ $\text{TSH} < 34 \mu\text{U/mL S and T4} > 8.0 \mu\text{g/dL}$ | $\text{TSH} < 34 \mu\text{U/mL S and T4} \leq 8 \mu\text{g/dL at } \geq 24 \text{ to } \leq 48 \text{ hrs}$ – Moderate $34 \leq \text{TSH} < 50 \mu\text{U/mL S and T4} > 8 \mu\text{g/dL at } \geq 24 \text{ to } \leq 48 \text{ hrs}$ – Moderate $34 \leq \text{TSH} < 50 \mu\text{U/mL S and T4} \leq 8 \mu\text{g/dL at } \geq 24 \text{ to } \leq 48 \text{ hrs}$ – Elevated $\text{TSH} < 0.5 \mu\text{U/mL S and T4} \leq 8 \mu\text{g/dL}$ – Moderate $\text{TSH} \geq 50 \mu\text{U/mL S}$ – Elevated | TSH results will be reported as Inconclusive if age at collection is not provided or if specimen is collected at < 24 hours of age. TSH results are reported as uU/mL S, where S denotes serum, and are calculated (not actually measured in serum) based on conversion factors that assume 55% hematocrit (actual hematocrit is not measured). |
| | For specimens collected at > 48 hours of age: $\mu\text{U/mL S} \leq \text{TSH} < 28 \mu\text{U/mL S}$ $\text{TSH} < 28 \mu\text{U/mL S and T4} > 8.0 \mu\text{g/dL}$ | $\text{TSH} < 28 \mu\text{U/mL S and T4} \leq 8 \mu\text{g/dL at } > 48 \text{ hrs to } \leq 168 \text{ hrs}$ – Moderate $28 \leq \text{TSH} < 50 \mu\text{U/mL S and T4} > 8 \mu\text{g/dL at } > 48 \text{ hrs to } \leq 168 \text{ hrs}$ – Moderate $28 \leq \text{TSH} < 50 \mu\text{U/mL S and T4} \leq 8 \mu\text{g/dL at } > 48 \text{ hrs to } \leq 168 \text{ hrs}$ – Elevated $\text{TSH} < 0.5 \mu\text{U/mL S and T4} \leq 8 \mu\text{g/dL}$ – Moderate $\text{TSH} \geq 50 \mu\text{U/mL S}$ – Elevated | |
| | For specimens collected at > 168 hours of age: $\mu\text{U/mL S} < \text{TSH} < 10 \mu\text{U/mL S}$ $\text{TSH} < 10 \mu\text{U/mL S and T4} > 8.0 \mu\text{g/dL}$ | $\text{TSH} < 10 \mu\text{U/mL S and T4} \leq 8 \mu\text{g/dL at } > 168 \text{ hrs}$ – Moderate $10 \leq \text{TSH} < 50 \mu\text{U/mL S and T4} > 8 \mu\text{g/dL at } > 168 \text{ hrs}$ – Moderate $10 \leq \text{TSH} < 50 \mu\text{U/mL S and T4} \leq 8 \mu\text{g/dL at } > 168 \text{ hrs}$ – Elevated $\text{TSH} < 0.5 \mu\text{U/mL S and T4} < 8 \mu\text{g/dL}$ – Moderate $\text{TSH} \geq 50 \mu\text{U/mL S}$ – Elevated | |
| Biotinidase | Biotinidase > 17 MRU | Biotinidase ≤ 17 MRU – Elevated | Biotinidase will be reported as Inconclusive if specimen is collected following a transfusion. |
| IRT (Cystic Fibrosis) | IRT ≤ 96%ile of daily results OR 160 ng/mL and no mutations on CFTR test panel detected | 2 or more CFTR mutations – Elevated 1 CFTR mutation and IRT > 160 ng/mL – Elevated 1 CFTR mutation and IRT ≤ 160 ng/mL – Moderate 0 CFTR mutations and IRT > 160 ng/mL – Moderate | Risk of cystic fibrosis (IRT only or IRT and CFTR results) will be reported as Inconclusive if specimen is collected following a transfusion and if results of CFTR mutational analysis are not reproducible or not obtained due to DNA amplification failure. The IRT 96%ile is typically in the range of 56-65 ng/mL. |
| GALT | GALT > 2.0 U/gHb | GALT > 1.0 and ≤ 2.0 U/gHb - Moderate GALT ≤ 1.0 U/gHb OR GALT ≤ 2.0 and TGal ≥ 20 mg/dL - Elevated | GALT results will be reported as Inconclusive if specimen is collected following a transfusion. |
| Hemoglobin | FA | Any result other than FA, with the exception of AF on known transfusion cases FA + any variant – Hemoglobin Trait FS, FC, FSC, or any result lacking Hgb A – Hemoglobin Disease FCA, FSA, or any variant with higher % than Hgb A – Hemoglobin Disease | Hemoglobin results will be reported as Inconclusive if specimen is collected following a transfusion. |
| TREC | TREC CT < 37.000 | $37.0 \leq \text{TREC CT} < 39.9$ (Decreased) and NICU = No, BW < 2500g – Moderate $37.0 \leq \text{TREC CT} < 39.9$ (Decreased) and NICU = No, BW ≥ 2500g, Age ≤ 5 days – Moderate $37.0 < \text{TREC CT} < 39.9$ (Decreased) and NICU = No, BW ≥ 2500g, Age > 5 days – Elevated TREC CT ≥ 39.9 (Absent) and NICU = No, BW ≥ 2500g – Elevated TREC CT ≥ 37.0 (Decreased) and NICU = Yes, Age ≤ 28 days – Moderate TREC CT ≥ 37.0 (Decreased) and NICU = Yes, Age > 28 days – Elevated | TRECs amplification within reference range is an indicator of normal T cell production; the reference range for the TREC test is "Normal T cell production". A TREC result of "Decreased" corresponds to decreased TREC DNA amplification and indicates low T-cell production (outside reference range). A TREC result of "Absent" corresponds to no TREC DNA amplification and indicates no T cell production (outside reference range). Risk Level is Inconclusive in the event of DNA amplification failure for both TREC and other unreported reference sequence. |
| SMN1 | SMN1 CT < 29.0 | SMN1 CT ≥ 29.0 (Decreased) - Elevated | Risk Level is Inconclusive in the event of DNA amplification failure for unreported reference sequence. |
| X-ALD | < 0.18 μmol/L | ≥ 0.18 μmol/L - Elevated | |

effective 10/23/2022